Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors
Nurix Therapeutics (Nasdaq: NRIX) has appointed Roy D. Baynes, MB.Bch., M.Med., Ph.D. to its board of directors. Dr. Baynes, currently executive vice president and chief medical officer of Eikon Therapeutics, brings over 22 years of clinical leadership experience in pharmaceutical and biotech companies.
Previously serving as chief medical officer at Merck, Dr. Baynes supervised the clinical portfolio and developed strategies for numerous medicines, including pembrolizumab (Keytruda). He has been a member of Nurix's Medical Advisory Board since 2023 and has expressed particular interest in the company's protein degradation science and clinical trials of NX-5948 in patients with CLL and Waldenström macroglobulinemia.
Nurix Therapeutics (Nasdaq: NRIX) ha nominato Roy D. Baynes, MB.Bch., M.Med., Ph.D. nel suo consiglio di amministrazione. Il Dr. Baynes, attualmente vicepresidente esecutivo e chief medical officer di Eikon Therapeutics, porta con sé oltre 22 anni di esperienza nella leadership clinica in aziende farmaceutiche e biotecnologiche.
In precedenza, come chief medical officer di Merck, il Dr. Baynes ha supervisionato il portafoglio clinico e sviluppato strategie per numerosi farmaci, incluso il pembrolizumab (Keytruda). È membro del Consiglio Consultivo Medico di Nurix dal 2023 e ha espresso un particolare interesse per la scienza della degradazione delle proteine dell'azienda e per gli studi clinici di NX-5948 in pazienti con CLL e macroglobulinemia di Waldenström.
Nurix Therapeutics (Nasdaq: NRIX) ha nombrado a Roy D. Baynes, MB.Bch., M.Med., Ph.D. en su junta directiva. El Dr. Baynes, actualmente vicepresidente ejecutivo y director médico de Eikon Therapeutics, aporta más de 22 años de experiencia en liderazgo clínico en empresas farmacéuticas y biotecnológicas.
Anteriormente, como director médico en Merck, el Dr. Baynes supervisó el portafolio clínico y desarrolló estrategias para numerosos medicamentos, incluido el pembrolizumab (Keytruda). Ha sido miembro del Consejo Asesor Médico de Nurix desde 2023 y ha expresado un interés particular en la ciencia de degradación de proteínas de la empresa y en los ensayos clínicos de NX-5948 en pacientes con CLL y macroglobulinemia de Waldenström.
Nurix Therapeutics (Nasdaq: NRIX)는 Roy D. Baynes, MB.Bch., M.Med., Ph.D.를 이사회의 일원으로 임명했습니다. 현재 Eikon Therapeutics의 부사장 겸 최고 의학 책임자인 Baynes 박사는 제약 및 생명공학 회사에서 22년 이상의 임상 리더십 경험을 가지고 있습니다.
이전에 Merck의 최고 의학 책임자로 재직하며, Baynes 박사는 임상 포트폴리오를 감독하고 여러 의약품에 대한 전략을 개발했습니다. 여기에는 pembrolizumab (Keytruda)가 포함됩니다. 그는 2023년부터 Nurix의 의료 자문 위원회 위원으로 활동하고 있으며, 회사의 단백질 분해 과학과 CLL 및 Waldenström 거대단백혈증 환자에 대한 NX-5948의 임상 시험에 특별한 관심을 보였습니다.
Nurix Therapeutics (Nasdaq: NRIX) a nommé Roy D. Baynes, MB.Bch., M.Med., Ph.D. au sein de son conseil d'administration. Le Dr Baynes, actuellement vice-président exécutif et directeur médical d'Eikon Therapeutics, possède plus de 22 ans d'expérience en leadership clinique dans des entreprises pharmaceutiques et biotechnologiques.
Auparavant, en tant que directeur médical chez Merck, le Dr Baynes a supervisé le portefeuille clinique et développé des stratégies pour de nombreux médicaments, y compris le pembrolizumab (Keytruda). Il est membre du Conseil Consultatif Médical de Nurix depuis 2023 et a exprimé un intérêt particulier pour la science de la dégradation des protéines de l'entreprise et les essais cliniques de NX-5948 chez des patients atteints de CLL et de macroglobulinémie de Waldenström.
Nurix Therapeutics (Nasdaq: NRIX) hat Roy D. Baynes, MB.Bch., M.Med., Ph.D. in seinen Vorstand berufen. Dr. Baynes, der derzeit als Executive Vice President und Chief Medical Officer von Eikon Therapeutics tätig ist, bringt über 22 Jahre Erfahrung in der klinischen Leitung in pharmazeutischen und biotechnologischen Unternehmen mit.
Vorher war er Chief Medical Officer bei Merck, wo Dr. Baynes das klinische Portfolio überwachte und Strategien für zahlreiche Medikamente, einschließlich Pembrolizumab (Keytruda), entwickelte. Seit 2023 ist er Mitglied des Medizinischen Beratungsgremiums von Nurix und hat besonderes Interesse an der Proteinabbau-Wissenschaft des Unternehmens sowie an den klinischen Studien zu NX-5948 bei Patienten mit CLL und Waldenström-Makroglobulinämie geäußert.
- Appointment of highly experienced pharmaceutical executive with proven track record in developing blockbuster drugs
- Addition of expertise in clinical development and commercialization strategy
- Board member already familiar with company's technology through prior advisory role
- None.
Dr. Baynes has been a member of Nurix’s Medical Advisory Board since 2023
SAN FRANCISCO, March 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, announced today the appointment of Roy D. Baynes, MB.Bch., M.Med., Ph.D., to its board of directors. Dr. Baynes, who currently serves as executive vice president and chief medical officer of Eikon Therapeutics, has had a distinguished career in hematology and oncology and over 22 years of clinical leadership experience in pharmaceutical and biotech companies.
“Roy has been a trusted advisor to Nurix since 2023, and I am delighted to welcome him to our board of directors at this exciting time for the Company,” said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. “His extensive experience in the development of innovative, blockbuster medicines will be invaluable as we advance our pipeline across oncology and autoimmune indications.”
“As a clinical advisor, I have been deeply impressed by Nurix’s compelling science of protein degradation and the data that have been generated in the clinical trials of NX-5948 in patients with CLL and Waldenström macroglobulinemia, particularly in the face of growing resistance to BTK inhibitors,” said Dr. Baynes. “I have thoroughly enjoyed working with this talented team of drug discoverers, and I look forward to my increased involvement in Nurix’s plans for the clinical development and commercialization of its growing pipeline.”
Prior to joining Eikon Therapeutics, Dr. Baynes was chief medical officer and head of global clinical development at Merck, where he supervised the entire clinical portfolio at Merck Research Laboratories and was the architect of the development strategy for dozens of important new medicines including pembrolizumab (Keytruda), a humanized monoclonal antibody used in cancer immunotherapy that treats multiple tumor types as well as two histology agnostic indications. Earlier in his career, Dr. Baynes served as Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences, Inc., as Vice President of Global Development and head of the hematology/oncology development team at Amgen, Inc., and as Professor of Medicine at University of Kansas Medical Center and Wayne State University in Detroit, where he held the Charles Martin endowed chair of Cancer Research. Dr. Baynes holds an MB.BCh. (Bachelor of Medicine and Surgery), an M.Med. (specialist registration in Internal Medicine), and a Ph.D. from the University of Witwatersrand.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix’s partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements regarding the expected contributions Dr. Baynes will bring to Nurix and Nurix’s plans for the development and commercialization of its pipeline, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, the risks described under the heading “Risk Factors” in Nurix’s Annual Report on Form 10-K for the period ended November 30, 2024, and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect Nurix’s business and results of operations, which could, in turn, have a significant and adverse impact on Nurix’s stock price. Nurix cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nurix undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.
Contacts:
Investors
Jason Kantor, Ph.D.
Nurix Therapeutics, Inc.
ir@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FAQ
What experience does Roy Baynes bring to Nurix Therapeutics' board?
What are the key clinical trials NRIX is currently conducting?
How long has Dr. Baynes been associated with NRIX before joining the board?
What is NRIX's main therapeutic focus?
